OMGA

Omega Therapeutics, Inc. (OMGA) | Rumor.io

Omega Therapeutics

OMGA

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about OMGA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Feb 25

Omega Therapeutics, Inc. (OMGA) has filed for bankruptcy and will sell substantially all of its assets to PM08-B for a credit bid of at least $11,461,086.
The company's stock is listed on the OTC Pink market.
There are concerns about the company's financial health and the potential for further declines in its stock price.

Generated by AI

Sentiment

Of the messages about OMGA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100%	100% +17.05
Bearish	0%	0%	0%	0% -17.05

Bullish· Feb 13

Omega Therapeutics, Inc. ($OMGA) has the potential to reach $2 by next week, according to some optimistic predictions.
The stock has seen a significant increase in value, with some traders making profits of up to 0.18, and new investors entering the market.
Institutions own a large chunk of $OMGA, making it a potentially lucrative play for those looking to take advantage of the stock's growth potential.

Bearish· Feb 13

The technology behind Omega Therapeutics, Inc. is flawed and has severe limits, making its epigenetic controllers less competitive with gene editing.
The company is accused of lying through its teeth, which may indicate a lack of transparency and potentially harm its reputation.
The stock market is seen as corrupt, with the SEC being criticized for not stopping short selling, which may contribute to the bearish sentiment towards Omega Therapeutics, Inc.

Generated by AI

Topics

Of the messages about OMGA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	0%
Announcements	—	—	100%	100%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	0%

Announcements· Jan 5

Omega Therapeutics, Inc. (OMGA) has secured a $532 million deal with Novo Nordisk, validating its unique technology.
The collaboration with Ozempic creator Novo Nordisk has led to a significant increase in trading volume, with over 85M shares traded in one day.
The deal has boosted investor confidence, with institutional backing and a market cap of $300M, indicating strong future prospects for the company.

Technical Analysis· Jan 4

Omega Therapeutics, Inc. ($OMGA) has seen significant price movement, doubling on a collaboration with Novo on an obesity drug development.
Technical analysis suggests a potential push higher for $OMGA, with some traders identifying a cup and handle pattern and a bull flag on the 5-minute chart.
The stock's daily chart shows a possible breakout above the 200-day SMA, with some traders taking a long position on the stock after it took out opening range highs.

Generated by AI

Community

Of the messages about OMGA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	23.53%
Newcomers	100%	100%	100%	76.47%

Regulars· Jan 4

$OMGA shares climbed 125% on research partnership with $NVO, with potential payments of up to $532M.
Omega Therapeutics, Inc. traded 28983% above average volume, with $OMGA up 117.48%, indicating strong interest in the stock.
$OMGA had an unusually high call volume of 1.7K, representing 19.9K% of the 30d avg call volume, and an unusually high put volume of 515, representing 3.3K% of the 30d avg put volume.

Newcomers· Jan 4

$OMGA is experiencing high trading volume, indicating market interest in the stock.
The company is making partnerships with pharmaceutical giants, such as Novo Nordisk, to develop new treatment approaches for obesity.
Newcomers are optimistic about the stock's potential, with some comparing its ticker symbol to "OMG" and others expressing enthusiasm for the company's epigenetic editing technology.

Generated by AI

News

Geron Announces Appointment of Chinmaya Rath as Chief Business Officer

Detailed price information for Geron Corp (GERN-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Also Discussed

Investors talking about OMGA also mention

#	Name	Attention
1	C4 Therapeutics IncCCCC	0%new
2	Ocean Biomedical Inc.OCEA	0%0
3	LVTX - LAVA Therapeutics N.V.	——
4	Ainos, Inc.AIMD	0%+0
5	Avenue Therapeutics Inc.ATXI	0%new
6	MINM - Minim, Inc.	——
7	Nkarta, Inc.NKTX	0%0
8	Immuneering Corp. Class A Common StockIMRX	0%0
9	TCTM - TCTM Kids IT Education Inc.	——
10	NEXI - NexImmune, Inc.	——